Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions

Status Recruiting

Clinical Trial Summary

Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care. The primary objective is the compilation of case reports, where pharmacogenetic testing is applied to determine the hereditable component of the patient's susceptibility to experience therapy failure and/or adverse drug reactions. The experience with the compiled cases will be basis for the development of a reliable standard of procedure for pharmacogenetic testing in the community pharmacy. The cases will be supplemented with information on additional Parameters reported in the literature to affect efficacy or safety of the respective drug.

Clinical Trial Description

Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care. Health-related data of patients experiencing therapy failure (TF) or adverse drug reaction (ADR) is collected and will then be supplemented with pharmacogenetic testing during pharmaceutical care in a study pharmacy. The patient data (diagnoses, medications and results of pharmacogenetic testing) is harmonized in order to generate a compilation of case reports. The primary objective is the compilation of case reports, where pharmacogenetic testing is applied to determine the hereditable component of the patient's susceptibility to experience therapy failure and/or adverse drug reactions. The experience with the compiled cases will be basis for the development of a reliable standard of procedure for pharmacogenetic testing in the community pharmacy. The cases will be supplemented with information on additional Parameters reported in the literature to affect efficacy or safety of the respective drug. ;

Study Design

Related Conditions & MeSH terms

Adverse Drug Reaction
Drug-Related Side Effects and Adverse Reactions
Therapy Failure

Clinical Trial Details

NCT number	NCT04154553
Study type	Observational
Source	University Hospital, Basel, Switzerland
Contact	Samuel Allemann, Prof. Dr.
Phone	+41 61 207 61 76
Email	s.allemann@unibas.ch
Status	Recruiting
Phase
Start date	October 15, 2019
Completion date	August 2026

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT02559960` - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed	`NCT01946919` - Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
Completed	`NCT01732302` - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients	N/A
Completed	`NCT05224804` - Pharmacists' Knowledge and Attitudes About ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals
Completed	`NCT02297126` - A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program	N/A
Completed	`NCT03093818` - PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions	N/A
Not yet recruiting	`NCT04568668` - Evaluating ActionADE in Reducing Adverse Drug Reactions	N/A
Recruiting	`NCT02012504` - Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients	Phase 0
Completed	`NCT01872520` - Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study	N/A
Completed	`NCT01467050` - Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients	Phase 4
Completed	`NCT01679964` - Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study	Phase 4
Completed	`NCT02094638` - Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study	N/A
Recruiting	`NCT01906710` - the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes	N/A
Completed	`NCT02888834` - Serious Adverse Drug Reaction and Their Preventability	N/A
Completed	`NCT02838212` - Adverse Drug Reactions With Fatal Outcome	N/A
Completed	`NCT02159209` - The Drug Induced Renal Injury Consortium	N/A
Completed	`NCT02134587` - Educational Intervention in Pharmacovigilance for Hospital Health Professionals	N/A
Completed	`NCT04553107` - Reducing Costs by Deprescribing Medications	N/A
Recruiting	`NCT06219720` - The Texas Interprofessional Pharmacogenomics (IPGx)
Recruiting	`NCT05508763` - Personalised Therapeutics @LUMC

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms